Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(tenofovir disoproxil fumarate + lamivudine) or (emtricitabine + efavirenz) + calcium + vitamin D
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This investigational regimen consists of a standard-of-care antiretroviral therapy (ART) backbone—comprising tenofovir disoproxil fumarate (TDF), efavirenz (EFV), and either lamivudine (3TC) or emtricitabine (FTC)—supplemented with calcium carbonate and vitamin D2 (ergocalciferol). Developed by Mahidol University, the combination is intended to treat HIV-1 infection while proactively addressing the common side effect of TDF-induced bone mineral density (BMD) loss. TDF is a nucleotide reverse transcriptase inhibitor (NRTI) known to cause renal phosphate wasting and altered bone metabolism. The addition of calcium and vitamin D aims to attenuate this bone loss by supporting bone mineralization and calcium homeostasis. The regimen was evaluated in an open-label, randomized controlled trial (NCT02827643) in Thailand.
- Brand names
- Atripla
- Other names
- tenofovir disoproxil fumarate + lamivudine + efavirenz + calcium + vitamin Dtenofovir disoproxil fumarate + emtricitabine + efavirenz + calcium + vitamin DCalcium and Vitamin D for Bone Loss in HIV Patients on TDF
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseVDR (Vitamin D receptor)HydroxyapatiteHBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on (tenofovir disoproxil fumarate + lamivudine) or (emtricitabine + efavirenz) + calcium + vitamin D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on (tenofovir disoproxil fumarate + lamivudine) or (emtricitabine + efavirenz) + calcium + vitamin D.